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Abstract
Anemia of chronic disease (ACD) is the result of altered iron metabolism, blunted erythropoiesis, and shortened red blood cell 
survival caused by inflammatory cytokines. Hepcidin plays a key role in anemia of chronic disease by inducing endocytosis of 
the iron exporter ferroportin. Iron is trapped in enterocytes, hepatocytes, and macrophages, and is unavailable for hemoglobin 
synthesis. When treating the underlying disease is not an option, or anemia is severe, ACD should be treated.  While oral iron 
supplementation is not suitable for ACD, intravenous iron may be effective. Erythropoiesis stimulating agents are a common ap-
proach to treating ACD, but a large percentage of ACD patients are refractory to ESAs. Additionally, there are many safety issues 
associated with ESA therapy. Concomitant IV iron supplementation increases patient response to ESAs and may reduce safety 
concerns as well. Several new, more targeted approaches to ACD treatment are being studied. Isocitrate supplements have been 
shown to improve ACD by minimizing the iron restriction response to increase erythropoiesis. Antibodies such as infliximab and 
tocilizumab, which neutralize the inflammatory cytokines TNF-α and IL-6, respectively, decrease hepcidin expression and improve 
hemoglobin levels. Finally, antibodies and speigelmers that target hepcidin directly are being developed. These new therapies, alone 
or in combination with IV iron or ESAs, show promise in alleviating anemia of chronic disease.
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Introduction 
Iron is an essential element for life. From the smallest 
microbes to the most complex of organisms, all require 
this vital nutrient to survive. As such, one of our bodies’ 
many host defense mechanisms is to limit the amount of 
iron available to pathogens. Inflammatory cytokines cause 
an increase in the expression of hepcidin, a liver protein 
that is a key regulator of iron metabolism. Hepcidin binds 
to ferroportin, the only known exporter of cellular iron, 
and causes it to be internalized and degraded (Nameth 
et al., 2004a). Thus, iron is trapped inside the cells, out of 
reach of bacteria, cancer cells, or other pathogens.
When inflammation becomes chronic, however, this 
innate defense mechanism becomes counterproductive. 
Too much of the iron from senescent red blood cells is 
sequestered within macrophages, rather than recycled 
for erythropoiesis. Patients with chronic inflammation 
often develop a unique form of anemia, known as the ane-
mia of chronic disease (ACD). ACD is the second most 
common type of anemia, caused by some cancers, chronic 
infections such as HIV, autoinflammatory diseases such 
as rheumatoid arthritis, and other diseases that feature 
chronic inflammation such as inflammatory bowel disease 
or heart disease. While treatment for these patients must 
focus primarily on curing the underlying disease, treat-
ing the anemia may greatly improve the patients’ quality 
of life. Because of the unique mechanism by which the 
anemia develops, treatment of ACD can be complicated. 
Treatments often used to treat other forms of anemia, 
such as iron deficiency anemia, may be ineffective, or 
even detrimental. This paper examines several possible 
approaches for treating anemia of chronic disease, given 
its unique pathogenesis. 
Methods
The information in this article was compiled by review 
and analysis of articles located using PubMed, ProQuest, 
and Google Scholar. Access was provided by the Touro 
College Library system. Emphasis was placed on origi-
nal studies, although review articles were also used. 
References cited in the articles provided further read-
ing. Articles discussing anemia of chronic kidney disease 
(ACKD), a related but different disorder were not includ-
ed in this review.
Discussion: 
Pathogenesis of Anemia of Chronic Disease
Hepcidin is a small peptide containing multiple disulfide 
bonds that is secreted by the liver. It was first isolated 
from human urine (Park et al., 2001). Initially recognized 
for its anti-microbial properties, it soon became clear 
that hepcidin is a key regulator of iron metabolism. Iron-
overloaded mice overexpress mRNA coding for a peptide 
closely homologous to human hepcidin. Additionally, iron 
depletion results in a decrease in hepcidin expression 
(Pigeon et al., 2001). Genetically modified mice overex-
pressing hepcidin were born with pale skin and died soon 
after birth. Those that survived had severe microcytic 
iron deficiency anemia (Nicolas et al., 2002a). 
A 2004 study by Nameth et al. provided a break-
through toward understanding the role of hepcidin in 
iron homeostasis. Using in vitro cells expressing fer-
roportin (Fpn) labeled with green fluorescent protein 
(Fpn-GFP), they demonstrated the effect of hepcidin on 
ferroportin. Hepcidin binds directly to Fpn, inducing its 
endocytosis. Upon addition of hepcidin, Fpn-GFP disap-
pears from the cell surface, and is localized in intracellular 
vesicles. (Nameth et al., 2004a). Hepcidin binds directly 
to ferroportin and induces rapid ubiquitination of several 
lysine residues of ferroportin. This tags ferroportin for 
internalization (Qiao et al., 2012). Ferroportin is subse-
quently degraded by lysozymes.  
Ferroportin (also called MTP-1) is an iron transporter 
located at the surface of cells involved in iron metabolism, 
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including duodenal enterocytes, hepatocytes, macrophages, 
and placental cells. It is structurally similar to the DMT1 
class of metal transporters (Abboud and Haile, 2000). 
Ferroportin acts as an iron exporter, releasing iron into 
the bloodstream. Fpn null/null mice are not embryonically 
viable. Inactivation of ferroportin at birth results in severely 
anemic mice with accumulation of non-heme bound iron 
in enterocytes, macrophages, and hepatocytes (Donovan 
2005). In vitro, cells expressing ferroportin only in the pres-
ence of an inducer, accumulate ferritin when ferroportin is 
inactive. Induction of ferroportin results in a clearance of 
ferritin from the cell (Nameth et al., 2004a). 
There are no known cellular iron exporters other 
than ferroportin. The removal of ferroportin from the 
cell surface inhibits transport of iron to the serum. Iron 
is trapped within the cell and stored as ferritin. Hepcidin 
levels, and thus ferroportin levels, are modulated by 
serum iron levels. Iron overload activates a BMP (Bone 
Morphogenetic Protein)/ SMAD signaling pathway which 
causes increased hepcidin expression. Hemojuvelin, a pro-
tein that is mutated in juvenile hemochromatosis patients, 
plays an important role in this pathway as a coreceptor of 
BMP (Babbit et al., 2006).  Hepcidin expression is down-
regulated in response to anemia and hypoxia, allowing the 
iron necessary for erythropoiesis to be released into the 
plasma (Nicolas et al., 2002b). 
Hepcidin also increases as part of the acute phase 
response to inflammation. The inflammatory cytokine 
Interleukin-6 (IL6) is the primary inducer of inflammatory 
upregulation of hepcidin mRNA expression. In vitro, the 
increase of hepcidin stimulated by inflammation is inhib-
ited by the addition of anti-IL6 antibodies. IL-6 infusion 
in humans causes an increase in urinary hepcidin, along 
with a decrease in serum iron and transferrin saturation 
(Nameth et al., 2004b).  IL-6 activates a JAK/STAT signal 
transduction pathway. The immediate -165 base pairs 
of the hepcidin promoter are necessary for hepcidin 
induction by IL-6. Deletion of the STAT binding motif 
within this promoter fragment inhibits IL-6 activation. 
In particular, the transcription factor STAT3 is required 
(Falzacappa et al, 2007). Chronic inflammation results in 
increased hepcidin and anemia in WT mice, but not in 
STAT3 knockout mice (Sakamori et al., 2010).
In patients with chronically elevated IL-6, hepcidin is 
persistently elevated. The resulting lack of ferroportin 
causes iron to be retained within the cells. Dietary iron is 
not absorbed into the plasma. Iron stored in hepatocytes 
of the liver is not released. Most significantly, iron from 
senescent erythrocytes is sequestered in macrophages 
in the spleen. Rats with ACD had higher levels of ferritin 
in the spleen than healthy controls, with less iron being 
released from macrophages (Theurl et al., 2010).  The re-
sulting hypoferremia limits the amount of iron available for 
erythropoiesis. 
In addition to the functional iron deficiency induced by 
hepcidin-mediated iron sequestering, inflammatory cyto-
kines have been shown to have other effects which contrib-
ute to anemia of chronic disease. Specifically, Interferon-γ 
(IFN-γ) has been shown to suppress erythropoiesis. 
Inflammation inhibits the wave of reticulocytosis normally 
seen in cells treated with erythropoietin (Epo) in vitro. 
Neutralization of IFN-γ reverses this effect. Treatment of 
mice with anti-INF-γ antibodies prevents inflammatory 
suppression of erythropoiesis (Thawani et al., 2006). This 
blunting of erythropoiesis may explain why ACD is often 
normocytic and normochromic. Other anemias caused by 
inappropriately high hepcidin levels, such as iron refractory 
iron deficiency anemia, are severely microcytic and hypo-
chromic. IFN-γ suppression of erythropoiesis seems to 
compensate for the lack of bioavailable iron by producing 
fewer normal RBCs, rather than many abnormal ones 
(Nameth & Ganz, 2014).
Further contributing to anemia, erythrocytes have a 
moderately shortened life span in inflammatory conditions. 
Biotin labeling of erythrocytes in mice showed a complete 
RBC turnover by day 15 in mice with inflammation, com-
pared to day 36 in control mice (Thawani et al., 2006). In 
humans, erythrocyte life span in patients with rheumatoid 
arthritis (RA), often used as a model for ACD, is significant-
ly shorter than in healthy controls. Red blood cells from 
these patients transfused into healthy individuals showed 
normal survival. This indicates that the shortened survival 
was not caused by defects in the red blood cells. Rather, 
inflammation causes a decrease in erythrocyte life span 
by some extrinsic mechanism (Freireich et al., 1957). The 
premature destruction of erythrocytes is likely the result 
of increased macrophage activity in the spleen in response 
to various cytokines (Nameth & Ganz, 2014). 
Tumor Necrosis Factor (TNF-α) and Interleukin-1 
(IL-1) were among the earliest inflammatory cytokines 
to be implicated in anemia of chronic disease. However, 
the mechanisms involved are still unclear. Both TNF-α 
and IL-1 reduce hepcidin expression in vitro (Song et 
al., 2013). It seems that their role in ACD is indirect, via 
regulation of other cytokines. Cytokine-cytokine interac-
tions are complex, and researchers still have a lot to learn 
before the pathogenesis of ACD can be fully understood.
Treating Anemia of Chronic Disease
Anemia of chronic disease is a secondary effect of an un-
derlying illness. ACD is usually mild. As such, the major 
focus of treatment protocols for ACD patients must be on 
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curing the primary disease. As the inflammation caused by 
the disease subsides, inflammatory cytokine levels return 
to baseline. Consequentially, the anemia will be resolved 
without the need for anemia-related treatment. However, 
often the underlying disease is not curable. Anemia may 
also have a profound negative impact on the patient’s 
quality of life. The most common complaint of patients 
with ACD is fatigue, which can be debilitating. In such 
cases, direct treatment of the anemia of chronic disease 
is recommended. As with any medical intervention, the 
benefits of treatment must be weighed carefully against 
any possible risks. It is important to note that anemia in 
chronically ill patients is often multifactorial. Anemia of 
chronic disease may occur in conjunction with true iron 
deficiency anemia, or anemia of another cause. It is nec-
essary to correctly diagnose the cause of anemia before 
deciding on a treatment option. Finally, certain treatments 
may not be suitable for certain patients, depending on 
which underlying disease is causing the inflammation.
Oral iron supplementation, the obvious solution for 
iron deficiency anemia, is not appropriate for anemia 
of chronic disease. The removal of ferroportin from the 
basolateral surface of duodenal enterocytes prevents 
oral iron from being adequately absorbed into the plas-
ma. Much of the minimal iron that is absorbed will be 
diverted into hepatocytes (Weiss & Goodnough, 2005). 
Intravenous iron therapy may be effective in treating ane-
mia of chronic disease, because parenteral administration 
allows it to bypass the “mucosal block” in the duodenum. 
Indeed, several trials have shown that IV iron therapy is 
beneficial for anemia of chronic disease in cancer patients. 
A pilot study showed a significant increase in hemoglobin 
levels in cancer patients with non-iron deficiency anemia 
in response to weekly doses of ferric hydroxide sucrose 
(Abdel-Rezeq et al, 2013). A single dose of ferric carboxy-
maltose improved hemoglobin levels in chemotherapy pa-
tients with ACD. This improvement was maintained for a 
minimum of 8 weeks. (Hedenus et al., 2014).  A large study 
comparing the efficacy of IV iron and oral iron supple-
mentation in cancer patients found that both treatment 
options induce a similar increase in hemoglobin levels, 
although the response time was faster for IV iron. IV iron 
also caused less side effects than oral iron. The efficacy 
of oral iron seen in this study is surprising, as it conflicts 
with many other studies. However, this study included pa-
tients with iron deficiency anemia (Birgegard et al, 2016). 
Trials that were specific to patients with functional iron 
deficiency showed IV iron to be superior. 
Several concerns have been raised regarding the safety 
of iron supplementation. Iron overload is associated with 
oxidative stress and cardiovascular events. Additionally, 
iron sequestering is an innate host defense mechanism. 
Iron supplementation may increase the risk of infections 
and tumor growth. (Weiss & Goodnough, 2005). Although 
the trials reported here have indicated that intravenous 
iron is safe for cancer patients, these trials only followed 
patients for short periods of time. Long-term studies 
are necessary to establish whether IV iron is truly safe 
for patients with anemia of chronic disease (Rodgers & 
Gilreath, 2019). Most of the research regarding efficacy 
of IV iron monotherapy for anemia of chronic disease has 
been in chemotherapy patients. Further experimentation 
is necessary to assess whether parenteral iron is useful in 
cases of ACD caused by illnesses other than cancer. 
Among the earliest treatment options available for 
anemia of chronic disease are Erythropoiesis Stimulating 
Agents (ESAs). This category includes recombinant human 
erythropoietin (rHuEpo) and its derivatives, Epoetin-α 
and Darbepoetin-α. ESAs target the blunted erythropoie-
sis characteristic of ACD and should minimize the iron-se-
questering effect of hepcidin as well.  Pharmacological lev-
els of erythropoietin cause a dose-dependent decrease 
in hepcidin expression in vitro (Pinto et al., 2008). In 
another study, pretreatment with erythropoietin partially 
prevented the increase in hepcidin normally induced by 
inflammation in mice. This effect was dose dependent. 
Pharmacological doses of Epo were effective, but the 
endogenous increase in erythropoietin in response to 
hypoxia was insufficient to reduce hepcidin expression. 
IL-6 levels were similar in Epo-treated and control mice. 
However, STAT3 phosphorylation decreased significantly. 
Suppression of STAT3 is likely the mechanism by which 
erythropoietin decreases IL-6 induced hepcidin expres-
sion (Huang et al., 2009). Erythropoiesis stimulating agents 
have been proven effective for ameliorating anemia of 
chronic disease in humans. In a placebo controlled double 
blind trial, normal hemoglobin levels were achieved in 
94% of rheumatoid arthritis patients with ACD treated 
with rHuEpo. Interestingly, rHuEpo also reduced disease 
activity in RA patients (Peeters et al., 1996).  ESAs are 
likewise used to treat anemia of chronic disease in cancer 
patients. 
Unfortunately, there are serious safety concerns re-
garding ESAs. Although few side effects were reported 
in early trials of ESAs for rheumatoid arthritis patients 
(Peeters et al., 1996, Nordström et al., 1997), ESA treat-
ment is associated with numerous adverse effects, es-
pecially in cancer patients. In a meta-analysis of 53 trials 
including close to 4,000 patients, mortality increased by 
17% in cancer patients with anemia treated with ESAs 
compared to controls (Bohlius et al., 2009). In 2007, 
the FDA issued a black box warning stating that “ESAs 
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increase the risk of death, myocardial infarction, stroke, 
venous thromboembolism, thrombosis of vascular ac-
cess, and tumor progression or recurrence [in cancer 
patients]”. Venous thromboembolism is one of the most 
prevalent adverse effects of ESAs. This may be because 
ESAs induce iron-deficient erythropoiesis (IDE), by in-
creasing erythropoiesis despite the lack of bio-available 
iron caused by ACD. This results in elevated platelet 
counts, which increases the risk for thrombolytic events 
(Henry et al., 2011).
Aside from increased safety concerns, the functional 
iron deficiency of ACD limits the efficacy of ESAs. Many 
patients do not respond to ESA treatment. Response 
rates vary from trial to trial. One study, in RA patients, 
reported that only 14.6% of patients achieved target 
hemoglobin levels. Decreased iron levels and more severe 
inflammation were predictive of a poor response. In an 
extension to the study, four out of five initial non-re-
sponders who were now given iron supplementation 
in addition rHuEpo treatment did show significant im-
provement in hemoglobin levels (Nordström et al., 1997). 
Hemoglobin does not increase significantly in response to 
ESAs in mice overexpressing hepcidin (Sasu et al., 2010). 
In another study, rats with higher pre-treatment levels of 
hepcidin, which correlates to lower iron availability, were 
shown to respond poorly to ESA treatment. Although 
ESAs decrease hepcidin expression somewhat, and thus 
decrease splenic iron retention, this effect is inadequate. 
Serum iron remains low, and ESA treatment does not 
effect an increase in hemoglobin in rats with very high 
hepcidin levels (Theurl et al., 2014). 
The limitations of iron-deficient erythropoiesis to ESA 
treatment has led researchers to investigate whether 
concomitant iron supplementation could improve the 
safety and efficacy of ESAs. Indeed, many studies have 
shown positive results when erythropoiesis stimulating 
agents are combined with intravenous iron. Parenteral 
iron administration is preferable to oral supplements, as 
oral iron is not well absorbed by patients with ACD.  IV 
iron could correct ESA-induced iron-deficient erythro-
poiesis and improve response to rHuEpo in rheumatoid 
arthritis patients with anemia of chronic disease (Arndt 
et al., 2005). Encouraging results were seen in cancer 
patients with ACD as well.  Patients receiving supple-
mental iron intravenously achieved higher hemoglobin 
levels in response to epoetin-α than patients receiving 
epoetin-α with oral iron or epoetin-α alone. Response 
rates were significantly improved in the IV iron group 
as well. In the IV iron group, 73% of patients responded 
to the ESA treatment, compared to only 45% and 41% 
in the oral and no iron groups, respectively (Henry et 
al., 2007). Auerbach et al. similarly reported that cancer 
patients who received combination of darbepoetin-α 
and IV iron were more likely to reach target hemoglo-
bin levels, with more rapid and significant improvement 
than patients who did not receive IV iron. Interestingly, 
the incidence of adverse effects, including thrombolytic 
events, was similar in both groups (Auerbach et al., 2010). 
By contrast, post-hoc analysis of data from the first study 
showed that IV iron decreased the likelihood of elevated 
platelet counts and venous thromboembolism (Henry et 
al., 2011). One trial failed to show a significant difference 
between chemotherapy patients receiving darbepoetin 
and intravenous ferric gluconate versus oral iron or oral 
iron placebos. Additionally, many adverse events were 
reported among those patients receiving parenteral iron 
(Steensma et al., 2010). However, this study had several 
limitations. The overall iron dose was lower than in other 
studies, potentially limiting the benefit of IV iron. By con-
trast, the individual doses of iron administered were 50% 
above the recommended dosage, which may explain the 
excessive number of adverse events. Finally, the study was 
terminated early, with few patients completing the study 
(Steensma et al., 2010 & Aapro et al., 2011). Nevertheless, 
the high incidence of adverse events in this study high-
lights the need for additional studies as to the safety of 
parenteral iron. 
Experimental Treatment Options
Another option for targeting the blunted erythropoiesis 
of ACD which is currently being studied is isocitrate sup-
plements. Aconitase is a Krebs’s cycle enzyme responsible 
for converting citrate into isocitrate. Insufficient iron lev-
els result in decreased aconitase activity, to produce less 
isocitrate. Aconitase activity is used by the body as an “iron 
sensor”. Decreased isocitrate results in downstream inhi-
bition of erythropoiesis by sensitizing erythroid progeni-
tor cells to the inhibitory effects of IFN-γ (Richardson, et 
al., 2013). This is known as the iron restriction response. 
Supplementation of exogenous isocitrate inhibits the iron 
restriction response via a PKC mechanism (Bullock et al., 
2010).  Isocitrate does not change serum or stored iron 
levels, nor does it alter erythropoietin levels (Kim et al., 
2016). Rather, it seems to “fool the system” into increas-
ing erythropoiesis despite hypoferremia.
Low doses of isocitrate supplementation reversed 
anemia of inflammation in a model of rat arthritis by 
preventing the iron restriction response (Richardson et 
al., 2013). However, later studies found that much higher 
doses were necessary to achieve even transient results 
in mice. Administration of high doses of isocitrate caused 
increased inflammation in these mice (Kim et al., 2016). 
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The necessity of such high doses to improve anemia of 
chronic disease may limit the efficacy of isocitrate as 
a treatment for ACD in humans. Recent research has 
shown that treatment with a combination of isocitrate 
and fumarate is effective in curing anemia of chronic 
disease in a murine model, even at low doses (Goldfarb 
et al., 2019). Further research, including human trials, is 
necessary to determine whether isocitrate may be a clin-
ically appropriate treatment for ACD. It seems reasonable 
to assume, however, that isocitrate treatment may have 
limitations similar to those seen with ESAs, as bypassing 
the iron restriction response would lead to iron deficient 
erythropoiesis. As with ESAs, supplementation with IV 
iron may be beneficial. 
ACD is caused by the result of the interaction of 
various cytokines. Recent research has focused on in-
hibition of these inflammatory signals using humanized 
antibodies as a target for treating anemia of chronic dis-
ease. Inhibition of Tumor Necrosis Factor-α (TNF-α) is 
a common treatment option for the auto-inflammatory 
disease Rheumatoid Arthritis. Treatment with infliximab, 
an anti-TNF-α antibody, reduces hepcidin levels and im-
proves blood parameters in RA patients. TNF-α alone 
actually decreases hepcidin mRNA expression in vitro. 
Paradoxically, TNF-α also upregulates IL-6 production, 
resulting in the downstream upregulation of hepcidin. 
Inhibition of TNF-α reduces IL-6, thereby indirectly re-
ducing serum hepcidin levels, albeit not as effectively as 
direct inhibition of IL-6 (Song et al., 2013). 
Tocilizumab, an IL-6 inhibitor used to treat multi-
centric Castleman’s disease (MCD) and rheumatoid ar-
thritis, effectively reduces anemia of chronic disease in 
these patients. Tocilizumab is a humanized anti-IL6 recep-
tor antibody. It binds to the IL-6 receptor and prevents 
IL-6 binding (Mihara et al., 2011). Tocilizumab completely 
inhibits IL-6 induction of hepcidin expression in vitro. 
Short-term treatment of MCD patients with tocilizumab 
results in decreased hepcidin and amelioration of anemia. 
These results continue when Tocilizumab was given over 
a longer period of time. Hepcidin expression keeps de-
creasing until normal serum hepcidin levels are reached 
and hemoglobin increases. Other iron-related parameters 
improve as well (Song et al., 2010). Tocilizumab decreases 
serum hepcidin and improves iron related blood parame-
ters including hemoglobin, serum iron, ferritin, and MCV 
in rheumatoid arthritis patients as well (Song et al., 2013). 
In monkeys with anemia of chronic disease, IL-6 blockade 
with tocilizumab caused a rapid decrease of serum hepci-
din. Hemoglobin levels and RBC improvement was dras-
tic at first, then slowed and gradually continued until they 
returned to pre-inflammation levels (Hashizume 2010). 
The amelioration of anemia by tocilizumab seems to be 
due to inhibition of IL-6 induction of hepcidin. However, 
as IL-6 plays a role in the pathogenesis of MCD and RA, 
and tocilizumab reduces disease symptoms, it may be that 
the improvement of the underlying disease plays a role in 
decreasing anemia as well. 
A major concern with tocilizumab treatment is its 
immunosuppressive effect and increased risk of infection. 
Additionally, since tocilizumab suppresses biomarkers 
of infection, it is necessary to observe patients closely 
for symptoms that may indicate infection (Mihara et al., 
2011). The STREAM study, which followed RA patients 
receiving tocilizumab monotherapy over a period of five 
years showed the drug to have a good safety profile. The 
majority of the adverse events reported were mild, and 
the benefits of the drug on patient quality of life out-
weighed these events (Nishimoto et al., 2009). It remains 
to be seen whether tocilizumab and other anti-cytokine 
antibodies are safe and effective for treating ACD caused 
by other diseases. 
Perhaps the most targeted approach to treating ACD 
is direct inhibition of hepcidin activity. Monoclonal anti-
bodies (mAbs) and speigelmers which bind to hepcidin 
and prevent its interaction with ferroportin are promising 
developments. A Phase-1 study of the anti-hepcidin mAb 
LY2787106 in humans showed that the antibody was safe 
and well-tolerated in cancer patients with few serious 
adverse effects reported. However, the drug elicited only 
a transient increase in serum iron, which did not translate 
into improved hepcidin, serum ferritin, and TSAT levels 
(Vadhan-Raj et al., 2017). While ineffective alone, this 
antibody may be useful in treating ACD in combination 
with other drugs. 
As an alternative to antibodies, Noxxon Pharma of 
Germany has developed an anti-hepcidin speigelmer 
called Lexaptepid Pegol (Nox-H94). Speigelmers are oli-
goribonucleotides with L-stereochemistry which bind to 
the target protein and inactivate it in a manner similar to 
antibodies. The advantage of a speigelmer over antibodies 
is that it does not elicit an immunological response in 
patients. Its L-stereochemistry prevents the development 
of anti-drug antibodies (ADAs) and also makes it nuclease 
resistant (Schwoebel et al., 2013). Indeed, patients receiv-
ing lexaptepid did not form antibodies specific to the 
drug (Boyce et al., 2016), while some patients receiving 
the mAb LY2787106 did develop ADAs (Vadhan-Raj et 
al., 2017). In vitro, lexaptepid inhibits the hepcidin-in-
duced decrease in ferroportin expression. In monkeys 
with ACD caused by IL-6 injection, lexaptepid pegol par-
tially improved reticulocyte hemoglobin levels, hemato-
crit, and erythrocyte counts (Schwoebel et al., 2013).  A 
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placebo controlled double blind study of lexaptepid pegol 
in healthy humans showed a dose-dependent increase 
in serum iron, transferrin saturation, and serum ferritin. 
Reticulocyte hemoglobin did not increase in healthy vol-
unteers but would be expected to increase in patients 
with ACD (Boyce et al., 2016).  Lexaptepid temporarily 
prevents the inflammation-induced hypoferremia caused 
by endotoxin injection in heathy individuals (van Eijk et 
al., 2014). While the results have been promising in trials 
involving healthy individuals, further trials in ACD patients 
are necessary in order to know whether Lexaptepid can 
be clinically useful. 
One aspect which may limit the effectiveness of both 
anti-hepcidin antibodies and speigelmers is the relatively 
high production rate of hepcidin. High doses of these hep-
cidin-binding ligands are necessary to keep up with pro-
duction of new hepcidin (Fung & Nameth, 2013). Further 
experimentation, particularly in patients with anemia of 
chronic disease, will show whether this indeed limits the 
clinical value of such treatments.  Even if these drugs are 
ineffective alone, they may be useful in combination with 
other treatments. Low dose antibody neutralization of 
hepcidin was shown to increase responsiveness to ESAs 
in mice with ACD. The combination of the antibody and 
darbepoetin-α completely corrected anemia in these 
mice (Sasu et al., 2010).  If this is shown to be the case 
in humans as well, these drugs could take the place of 
parenteral iron, thereby eliminating the potential safety 
hazards associated with IV iron. 
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